https://tonic.inserm.fr/wp-content/uploads/2019/09/equipe-homme-defaut-150x150.jpg
 

Soleakhena KEN

IR

    Abstracts rédigés ou co-rédigés

  • > Diffusion tensor imaging of white matter tracts in the normal equidae brain

    F. Labelle, G. Arribarat, S. Monteil, S. Ken, F. Audigie, H. Gros, JP. Desirat, P. Peran, A. Deviers, G. Mogicato

    EAVA (European Association of Veterinary Anatomists) - VIENNE

    Publications rédigées ou co-rédigées

  • > 35- Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging.

    Laprie A, Ken S, Filleron T, Lubrano V, Vieillevigne L, Tensaouti F, Catalaa I, Boetto S, Khalifa J, Attal J, Peyraga G, Gomez-Roca C, Uro-Coste E, Noel G, Truc G, Sunyach MP, Magné N, Charissoux M, Supiot S, Bernier V, Mounier M, Poublanc M, Fabre A, Delord JP, Cohen-Jonathan Moyal E.

    BMC Cancer. 2019 Feb 21;19(1):167. doi: 10.1186/s12885-019-5317-x.
  • > 10- Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging.

    Laprie A, Ken S, Filleron T, Lubrano V, Vieillevigne L, Tensaouti F, Catalaa I, Boetto S, Khalifa J, Attal J, Peyraga G, Gomez-Roca C, Uro-Coste E, Noel G, Truc G, Sunyach MP, Magné N, Charissoux M, Supiot S, Bernier V, Mounier M, Poublanc M, Fabre A, Delord JP, Cohen-Jonathan Moyal E.

    BMC Cancer. 2019 Feb 21;19(1):167. doi: 10.1186/s12885-019-5317-x.
  • > 41- Identification of a candidate biomarker from perfusion MRI to anticipate glioblastoma progression after chemoradiation.

    Khalifa J, Tensaouti F, Chaltiel L, Lotterie JA, Catalaa I, Sunyach MP, Ibarrola D, Noël G, Truc G, Walker P, Magné N, Charissoux M, Ken S, Peran P, Berry I, Moyal EC, Laprie A.

    Eur Radiol. 2016 Nov;26(11):4194-4203.
  • > Voxel-based evidence of perfusion normalization in glioblastoma patients included in a phase I-II trial of radiotherapy/tipifarnib combination.

    Ken S, Deviers A, Filleron T, Catalaa I, Lotterie JA, Khalifa J, Lubrano V, Berry I, Péran P, Celsis P, Moyal EC, Laprie A.

    J Neurooncol. 2015 Sep;124(3):465-73. doi: 10.1007/s11060-015-1860-8.